Immuneworks was founded by Indiana University School of Medicine researchers to develop and commercialize treatments for serious autoimmune lung diseases.
ImmuneWorks, Inc. today announced the initiation of its Phase I clinical trial to evaluate the safety, tolerability, and biologic effects of three doses of IW001 in patients suffering from idiopathic pulmonary fibrosis (IPF), a serious lung disease. The clinical trial will move the biotech company one step closer to commercialization of its lead IPF treatment compound. read more